ANN ARBOR, Mich., Sept. 7, 2023 /PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced new data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS), supports informed clinical decisions for first-line treatment of patients with non-small cell lung cancer (NSCLC) beyond the standard of care biomarker PD-L1 immunohistochemistry [...]

Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the launch of Strata Select™, a first-of-its-kind molecular profiling test for patients with advanced cancer. The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit. Strata Select is [...]

ANN ARBOR, Mich., Sept. 13, 2022 /PRNewswire/ -- Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced expansion of its clinical collaboration with Pfizer (NYSE: PFE) in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial. Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies [...]

ANN ARBOR, Mich., June 23, 2022 – Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center have joined as clinical trial sites in the Strata SentinelTM trial, a prospective, observational study of the StrataMRDTM minimal [...]

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- CB Insights today named Strata Oncology to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year's Digital Health 150 was unveiled live during CB Insights' annual Future of Health event. The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 [...]

ANN ARBOR, Mich., June 10, 2021 – Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that it has appointed healthcare and molecular diagnostics veteran and former Abbott executive Mark Szewczyk as Chief Commercial Officer. The addition of Szewczyk is the latest in a series of strategic appointments bolstering Strata [...]

Study to Evaluate Strata's Ability to Detect Tumor Recurrence using Liquid Biopsy and Monitor Treatment Effectiveness for Patients with Early-Stage Solid Tumors ANN ARBOR, Mich., Jan. 13, 2021 /PRNewswire/ -- Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced plans to begin enrolling the Sentinel Trial in the first half of 2021. [...]

Ann Arbor, Mich. October 27, 2020 — Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), has established coverage of the StrataNGSTM test for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/ or metastatic solid tumors. StrataNGSTM is a comprehensive [...]

ANN ARBOR, Mich., July 29, 2020 /PRNewswire/ -- Strata Oncology, Inc. , a precision oncology company advancing molecular indications for cancer therapies, today announced it has signed an agreement with BioMed Valley Discoveries Inc.. to accelerate patient identification and enrollment for BioMed Valley's Phase 2 study of BVD-523 (ulixertinib) for patients with advanced malignancies harboring MEK or atypical BRAF alterations [...]

ANN ARBOR, Mich., May 20, 2019 /PRNewswire/ -- Strata Oncology, Inc., a precision oncology company, today announced that data from its Strata Trial, a nationwide observational NGS screening protocol providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, will be presented in a poster at the upcoming 2019 American Society of Clinical Oncology (ASCO) [...]

ANN ARBOR, Mich., March 19, 2019 /PRNewswire/ -- Strata OncologyTM, a leading precision oncology company, today announced the launch of version 3.0 of StrataNGSTM, its pan-cancer assay for solid tumors. The updated 500-gene assay utilizes DNA and RNA from tumor samples to detect all clinically actionable biomarkers — including microsatellite instability (MSI), tumor mutational burden (TMB), and PD-L1 [...]

Ann Arbor, Mich.  September 5, 2018—Strata Oncology, Inc. today announced it is participating as a CLIA-certified/accredited laboratory for the precision medicine cancer trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131). The objective of this ongoing phase II trial, co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN [...]

Ann Arbor, MI, December 13, 2017 – Strata Oncology, a precision oncology company, today announced five leading healthcare systems have joined the Strata Precision Oncology NetworkTM (Network). Launched in February of 2017, and led by Strata Oncology, the Network is advancing precision oncology by providing advanced cancer patients routine tumor profiling and matching to a [...]

Dan Rhodes, CEO at Strata Oncology, a tumor sequencing company, says genetic sequencing is “absolutely the bottleneck” in finding patients who will benefit from targeted cancer drugs. His company is giving away free testing to cancer patients to help match them to experimental treatments being studied in clinical trials (see “Should We Sequence the DNA [...]

Colon, pancreatic, stomach, or ovarian cancer; it increasingly shouldn’t matter. In an era of precision medicine, the treatment approach should reflect the genetic makeup of the person’s tumor and the presence or absence of key biomarkers. That ethos was set in stone on Tuesday, with the landmark FDA approval of Merck’s checkpoint inhibitor, Keytruda (pembrolizumab), [...]

Strata Oncology has raised $12 million and teamed up with Thermo Fisher Scientific ($TMO) to embark on a campaign to sequence the tumors of 100,000 cancer patients for free. The large-scale, no-cost tumor sequencing initiative is seen by Strata as a way to increase the number of cancer patients who are molecularly matched to clinical [...]

NEW YORK (GenomeWeb) – Strata Oncology said today that it has raised $12 million in a Series A financing to fuel its tumor sequencing operations. The financing was co-led by Arboretum Ventures and Baird Capital, and included existing investor Michigan eLab. Ann Arbor, Michigan-based Strata said it will use the funds to implement the Strata [...]

Ann Arbor, MI-based precision medicine startup Strata Oncology announced last week that it has raised a $12 million Series A round. Arboretum Ventures and Baird Capital led the financing, with participation from Michigan eLab, a returning investor. Strata is on a mission to make tumor sequencing for cancer patients more accessible. As personalized genetic therapies to treat cancer advance and increasingly make [...]

Dan Rhodes said he got good advice in August on launching his new company, Strata Oncology Inc., at a conference put on by eLab Ventures, an Ann Arbor-based venture capital firm and one of his eventual investors. Called Michigan eLab Insights and held over three days at the Hotel Walloon on Walloon Lake near Petoskey, eLab's partners gathered [...]